A Phase 2 interventional study of VEC-162 in Circadian Rhythm Sleep Disorders, sponsored by Vanda Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-08-26.
Sponsored by Vanda Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States — 10 open to participants now, 10 under way, 1 of them phase 3. Sleep Disorders, Circadian Rhythm · United States.
Among the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, this one is the 30th largest by enrollment of the 54 interventional ones that give a count, is one of 2 that started in 2004, is one of 5 in phase 2, and was the 9th registered.
135 studies on the registry are indexed under Sleep Disorders, Circadian Rhythm; 25 are open to participants now.
Browse Sleep Disorders, Circadian Rhythm studies →10 of the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States are open now. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 16+
Leslie Swanson · Sites in United States
Ages 18–60
Axsome Therapeutics, Inc. · Sites in United States, Canada
Ages 18–65
Yale University · Sites in United States
Ages 18+
University of Colorado, Boulder · Sites in United States
Ages 16–40 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Sleep Disorders, Circadian Rhythm studies recruiting now, 7 (50%) set no upper age limit and 4 (29%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 59 across 102 interventional studies indexed under Sleep Disorders, Circadian Rhythm.
Median enrollment 50 across the 54 interventional studies, 55 across the 15 observational. Of the 57 that completed or were terminated, 20 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 69 have an industry lead sponsor. The 10 most frequent:
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Vanda Pharmaceuticals has 9 studies filed under Sleep Disorders, Circadian Rhythm — fewer than ten, so there is no comparison to draw.
5 of the studies in Sleep Disorders, Circadian Rhythm with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06568367Phase 3Axsome Therapeutics, Inc.Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | 2026-12 |
| NCT06226025Leslie SwansonCorrecting Circadian Rhythms to Breakthrough in Bipolar Disorder | 2026-12 |
| NCT06336525Brigham and Women's HospitalAdult Sleep Health in the Rural Appalachia and Mississippi Delta Region and Its Relationships With Cardiometabolic Health Disparities. | 2027-01-31 |
| NCT05463861Stanford UniversityLemborexant in Delayed Sleep Phase Syndrome | 2027-05-31 |
| NCT06809335Henry Ford Health SystemA Pilot of a Personalized Circadian mHealth to Improve Sleep in Night Shift Workers | 2027-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of VEC-162 compared to matching placebo on circadian phase shift and sleep parameters.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Circadian Phase Shift
Exposure response to VEC-162 on induction of circadian phase shift as measured by Dim Light Melatonin Onset (DLMO) was defined as the time change between Night 3 and Night 4 when melatonin production reached 25% of the maximum melatonin concentration. Samples below LOQ of the melatonin assay were assigned 5 pg/ml.
Time frame: Night 3 and Night 4
Mean Sleep Efficiency
Exposure response was measured by comparing the change in sleep efficiencies of VEC-162 and placebo treated subjects upon a sleep schedule phase advance. Sleep efficiency (total time asleep divided by the time allowed as an opportunity for sleep in a period multiplied by 100%, where time allowed for sleep was 8 hours or 480 minutes) was measured objectively by overnight polysomnographic recordings. Sleep efficiency was also compared in parts of the night by dividing the full night into thirds.
Time frame: Night 4 and Night 2
Wake After Sleep Onset (WASO), and Latency to Persistent Sleep (LPS)
Wake After Sleep Onset is defined as the total time that is scored as awake in a PSG occurring between sleep onset and lights-on prompt. Latency to Persistent Sleep is defined as the number of epochs (one 30-second interval of the sleep episode) from the beginning of the recording (lights-out) to the start of persistent sleep (first 20 consecutive non-wake state) divided by 2.
Time frame: Night 2 and Night 4
VEC-162 AUC
Time frame: Night 4
VEC-162 Cmax
Time frame: Night 4
VEC-162 Tmax
Time frame: Night 4
| Milestone | Placebo | 10 mg VEC-162 | 20 mg VEC-162 | 50 mg VEC-162 | 100 mg VEC-162 |
|---|---|---|---|---|---|
| Started | 8 | 9 | 8 | 7 | 7 |
| Completed | 8 | 8 | 8 | 7 | 7 |
| Not completed | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 |
Exposure response to VEC-162 on induction of circadian phase shift as measured by Dim Light Melatonin Onset (DLMO) was defined as the time change between Night 3 and Night 4 when melatonin production reached 25% of the maximum melatonin concentration. Samples below LOQ of the melatonin assay were assigned 5 pg/ml.
| Hours | Placebo | 10 mg VEC-162 | 20 mg VEC-162 | 50 mg VEC-162 | 100 mg VEC-162 |
|---|---|---|---|---|---|
| Circadian Phase Shift | -0.48 ± 0.84 | 0.18 ± 2.48 | -1.14 ± 0.46 | -0.50 ± 0.32 | -2.74 ± 1.95 |
Exposure response was measured by comparing the change in sleep efficiencies of VEC-162 and placebo treated subjects upon a sleep schedule phase advance. Sleep efficiency (total time asleep divided by the time allowed as an opportunity for sleep in a period multiplied by 100%, where time allowed for sleep was 8 hours or 480 minutes) was measured objectively by overnight polysomnographic recordings. Sleep efficiency was also compared in parts of the night by dividing the full night into thirds.
| % points | Placebo* | 10 mg VEC-162 | 20 mg VEC-162 | 50 mg VEC-162 | 100 mg VEC-162 |
|---|---|---|---|---|---|
| Full Night (% points) | -20.27 ± 18.72 | -7.77 ± 14.98 | -6.68 ± 12.69 | -5.87 ± 9.89 | -2.02 ± 4.94 |
| 1st Third of the Night (% points) | -12.30 ± 14.51 | -0.47 ± 12.39 | -7.81 ± 14.52 | 0.95 ± 7.79 | -5.63 ± 17.71 |
| 2nd Third of the Night (% points) | -34.92 ± 38.23 | -12.64 ± 13.83 | -5.11 ± 12.78 | -2.10 ± 4.14 | -2.30 ± 5.72 |
| 3rd Third of the NIght (% points) | -8.06 ± 29.69 | -10.51 ± 35.17 | -7.09 ± 26.24 | -16.48 ± 26.25 | 1.80 ± 14.15 |
Wake After Sleep Onset is defined as the total time that is scored as awake in a PSG occurring between sleep onset and lights-on prompt. Latency to Persistent Sleep is defined as the number of epochs (one 30-second interval of the sleep episode) from the beginning of the recording (lights-out) to the start of persistent sleep (first 20 consecutive non-wake state) divided by 2.
| minutes | Placebo | 10 mg VEC-162 | 20 mg VEC-162 | 50 mg VEC-162 | 100 mg VEC-162 |
|---|---|---|---|---|---|
| Latency to Persistent Sleep | 15.13 ± 21.25 | -8.25 ± 16.34 | 5.00 ± 11.89 | -3.71 ± 10.97 | -4.17 ± 6.93 |
| WASO* | 77.00 ± 91.01 | 40.56 ± 67.53 | 31.19 ± 53.80 | 31.21 ± 52.69 | 8.50 ± 20.39 |
| ng*hr/mL | 10 mg VEC-162 | 20 mg VEC-162 | 50 mg VEC-162 | 100 mg VEC-162 |
|---|---|---|---|---|
| VEC-162 AUC | 171.73 ± 118.51 | 482.00 ± 329.48 | 614.34 ± 488.08 | 1916.06 ± 601.35 |
| ng/mL | 10 mg VEC-162 | 20 mg VEC-162 | 50 mg VEC-162 | 100 mg VEC-162 |
|---|---|---|---|---|
| VEC-162 Cmax | 59.10 ± 39.22 | 139.94 ± 116.10 | 166.01 ± 164.94 | 417.80 ± 187.19 |
| hour | 10 mg VEC-162 | 20 mg VEC-162 | 50 mg VEC-162 | 100 mg VEC-162 |
|---|---|---|---|---|
| VEC-162 Tmax | 1.90 ± 1.78 | 2.04 ± 0.90 | 2.42 ± 0.59 | 3.03 ± 1.50 |
Collected over 1st dose to 30 days following last administration of study treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/8 (0%) | 8/8 (100%) |
| 10 mg VEC-162 | — | 0/9 (0%) | 8/9 (88.9%) |
| 20 mg VEC-162 | — | 0/8 (0%) | 7/8 (87.5%) |
| 50 mg VEC-162 | — | 0/7 (0%) | 7/7 (100%) |
| 100 mg VEC-162 | — | 0/7 (0%) | 7/7 (100%) |
| Event | Placebo | 10 mg VEC-162 | 20 mg VEC-162 | 50 mg VEC-162 | 100 mg VEC-162 |
|---|---|---|---|---|---|
| SomnolenceNervous system disorders | 4/8 | 3/9 | 2/8 | 5/7 | 2/7 |
| Haematocrit DecreasedInvestigations | 3/8 | 4/9 | 3/8 | 4/7 | 4/7 |
| Haemoglobin DecreasedInvestigations | 2/8 | 3/9 | 0/8 | 2/7 | 3/7 |
| Application Site IrritationGeneral disorders | 3/8 | 1/9 | 2/8 | 0/7 | 0/7 |
| Injection Site PainGeneral disorders | 1/8 | 1/9 | 1/8 | 2/7 | 1/7 |
| Application Site PainGeneral disorders | 1/8 | 0/9 | 0/8 | 2/7 | 1/7 |
| HeadacheNervous system disorders | 2/8 | 1/9 | 1/8 | 1/7 | 2/7 |
| NervousnessPsychiatric disorders | 0/8 | 0/9 | 0/8 | 2/7 | 0/7 |
| NauseaGastrointestinal disorders | 2/8 | 1/9 | 0/8 | 1/7 | 0/7 |
| Abdominal Pain UpperGastrointestinal disorders | 0/8 | 0/9 | 2/8 | 1/7 | 0/7 |
| Age, Continuous(years) | Placebo | 10 mg VEC-162 | 20 mg VEC-162 | 50 mg VEC-162 | 100 mg VEC-162 | Total |
|---|---|---|---|---|---|---|
| Mean | 27.5 ± 6.7 | 31.8 ± 7.4 | 32.5 ± 9.6 | 27.4 ± 6.2 | 30.4 ± 9.5 | 30.0 ± 7.9 |
| Sex: Female, Male(Participants) | Placebo | 10 mg VEC-162 | 20 mg VEC-162 | 50 mg VEC-162 | 100 mg VEC-162 | Total |
|---|---|---|---|---|---|---|
| Female | 5 | 3 | 4 | 4 | 4 | 20 |
| Male | 3 | 6 | 4 | 3 | 3 | 19 |
The record gives a start of Jul 2004, a primary completion of Mar 2005 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 9 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tasimelteon
Sleep Disorders, Circadian Rhythm →